Commercial-Scale Adenoviral Vector CDMOs

· updated as new inspection, certificate, and trial data enters the platform

Adenoviral Vector manufacturers on CDMO Signal: 4 listed, 4 with a Signal Score. Together they have 19 FDA inspections on file (including 6 NAI, 13 VAI and 0 OAI) and 16 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.

4
CDMOs tracked
4
Fully scored
1
With FDA records
19
FDA inspections
16
EMA/MHRA GMP certs

Adenoviral vector CDMOs make replication-deficient adenovirus for gene therapy and vaccines, using producer cell lines (e.g. HEK293), suspension bioreactors, and chromatographic purification. The platform reaches high titers, which suits vaccine-scale demand.

Selecting an adenoviral CDMO turns on serotype and producer-line experience, suspension scale, full/empty particle control, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 6 NAI (no action), 13 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (14), UNITED KINGDOM (10), Belgium (4), Netherlands (3), Canada (2).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
2
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
3
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
4
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
How we score CDMOs →

What to evaluate in a Adenoviral Vector CDMO

Producer line & serotype
Confirm experience with your serotype (Ad5 and others) and producer cell line, and whether the process is suspension-adapted for scale.
Scale & titer
Adenovirus reaches high titers for vaccine-scale demand. Match validated bioreactor scale to your dose and volume.
Particle quality
Full/empty particle ratio and aggregate control affect potency and safety. Ask about the analytics package.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Adenoviral Vector CDMOs — Frequently Asked Questions

How many Adenoviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 1 Adenoviral Vector CDMO with FDA inspection records and 16 EMA/MHRA GMP certificates across the group.
What should I look for in an adenoviral vector CDMO?
Confirm serotype and producer-line experience, a suspension process at your required scale, strong particle-quality analytics, and a clean FDA and EMA/MHRA record.
How is adenoviral vector manufacturing different from AAV?
Both are non-enveloped viral vectors made in HEK293-type lines, but adenovirus is larger and drives strong transient expression (suiting vaccines), while AAV is the workhorse for durable in vivo gene therapy.
Related modalities
AAV / Gene Therapy CDMOs Gene Editing CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector